Osteoporosis International

, Volume 17, Issue 11, pp 1645–1652 | Cite as

Compliance with drug therapy for postmenopausal osteoporosis

Original Article

Abstract

Introduction

Patient compliance with pharmacotherapy for osteoporosis is typically poor in clinical practice; less frequent dosing with bisphosphonates may improve compliance.

Methods

Using data from 49 US health plans, we identified all women aged ≥45 years with osteoporosis who initiated therapy with a bisphosphonate, calcitonin, estrogen, or raloxifene. Compliance was examined alternatively in terms of incidence of adherence failure (medication days <80% of possible) and persistence failure (gap in therapy ≥90 days), and was compared across treatment groups using Kaplan-Meier methods and Cox proportional hazards models.

Results

The study population included 18,822 women, 48% of whom initiated weekly bisphosphonate therapy. Overall risk of adherence failure was 47% at 3  months, 70% at 1  year, and 84% at 3  years. Risk of persistence failure was 47% at 1  year, and 77% at 3  years. In multivariate analyses, risk of adherence failure was higher for calcitonin (hazard ratio=2.7 vs weekly bisphosphonate therapy, p<0.01), but comparable for all other therapies. Relative risks of persistence failure were generally similar.

Conclusions

Approximately three-quarters of women who initiate osteoporosis drug therapy are non-adherent with treatment within 12  months, and almost 50% have discontinued such therapy by this time. Compliance with weekly bisphosphonate therapy is generally no better than that with osteoporosis medications requiring more frequent dosing.

Keywords

Adherence Compliance Osteoporosis Pharmacotherapy 

Notes

Acknowledgements

Funding for this research was provided by Amgen, Inc., Thousand Oaks, California. The authors thank Manjusha Gokhale, M.P.H. of Policy Analysis Inc. (PAI) for assistance with data management and data processing and Enkhe Badamgarav, M.D., M.P.H., of Amgen Inc. for valuable comments on the manuscript.

References

  1. 1.
    (2004) U.S. Department of Health and Human Services. Bone health and osteoporosis: A report of the Surgeon General. Rockville, MD, U.S. Department of Health and Human Services, Office of the Surgeon GeneralGoogle Scholar
  2. 2.
    Andrade SE, Sumit RM, Chan KA, Buist DSM, Go AS, Goodman M, et al (2003) Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 163:2052–2057CrossRefGoogle Scholar
  3. 3.
    Melton LJ III, Thamer R, Ray NF, et al (1997) Fractures attributable to osteoporosis: Report from the National Osteoporosis Foundation. J Bone Miner Res 12:16–23PubMedCrossRefGoogle Scholar
  4. 4.
    Eichner SF, Lloyd KB, Timpe EM (2003) Comparing therapies for postmenopausal osteoporosis prevention and treatment. Ann Pharmacother 37:744–746CrossRefGoogle Scholar
  5. 5.
    Feldstein AC, Nichols GA, Elmer PJ, Smith DH, Aickin M, Herson M (2003) Older women with fractures: Patients falling through the cracks of guideline-recommended osteoporosis screening and treatment. J Bone Joint Surg 85A:2294–2302Google Scholar
  6. 6.
    Cuddihy MT, Gabriel SE, Crowson CS, Atkinson EJ, Tabini C, O’Fallon M, et al (2002) Osteoporosis intervention following distal forearm fractures: A missed opportunity? Arch Intern Med 162:421–26PubMedCrossRefGoogle Scholar
  7. 7.
    Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA (2000) Treatment of osteoporosis: Are physicians missing an opportunity? J Bone Joing Surg 82-A(8):1063–1070Google Scholar
  8. 8.
    Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856–861PubMedCrossRefGoogle Scholar
  9. 9.
    Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008PubMedCrossRefGoogle Scholar
  10. 10.
    McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287PubMedCrossRefGoogle Scholar
  11. 11.
    Kayser J, Ettinger B, Pressman A (2001) Postmenopausal hormonal support: Discontinuation of raloxifene versus estrogen. Menopause 8:328–332PubMedCrossRefGoogle Scholar
  12. 12.
    Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N (1998) Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Managed Care Pharm 4:488–492Google Scholar
  13. 13.
    Newton KM, Buist DSM, Miglioretti DL, Beverly K, Hartsfield CL, Chan KA, et al (2005) The impact of comorbidities on hormone use: After the 2002 release of the Women’s Health Initiative. J Gen Intern Med 20:350–356PubMedCrossRefGoogle Scholar
  14. 14.
    Health Insurance Portability and Accountability Act of 1996, 42 USC §1320–d2Google Scholar
  15. 15.
    Public Welfare-Protection of Human Subjects; 45CFR 46 §46.101Google Scholar
  16. 16.
    Steiner JF, Earnest MA, University of Colorado Health Sciences Center (2000) Lingua Medica: The language of medication-taking. Ann of Intern Med 132:926–930Google Scholar
  17. 17.
    Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414–2419PubMedCrossRefGoogle Scholar
  18. 18.
    Ettinger B, Pressman A (1999) Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: Transdermal matrix patch versus oral estrogen therapy. Am J Managed Care 5:779–785Google Scholar
  19. 19.
    Watts NB, Worley K, Solis A, Doyle J, Sheer R (2004) Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: Results from a managed care administrative claims database. J Manag Care Pharm 10:142–151PubMedGoogle Scholar
  20. 20.
    Tosteson ANA, Grove MR, Hammond CS, et al (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216PubMedCrossRefGoogle Scholar
  21. 21.
    Yood RA, Emani S, Reed JI, Lewis BE, Lydick MCE (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968PubMedCrossRefGoogle Scholar
  22. 22.
    Women’s Health Initiative. Department of Health and Human Services, National Institutes of Health, The National Heart, Lung, and Blood Institute. Accessed at http://www.nhlbi.nih.gov/whi/index.html, February 17, 2006
  23. 23.
    Osterberg L, Blaschke T (2005) Drug Therapy: Adherence to Medication. N Engl J Med 353:487–497PubMedCrossRefGoogle Scholar
  24. 24.
    Sikka R, Xia F, Aubert RE (2005) Estimating medication persistency using administrative claims data. Am J Manag Care 11:449–457PubMedGoogle Scholar
  25. 25.
    Peabody JW, Luck J, Jain S, Bertenthal D, Glassman P (2004) Assessing the accuracy of administrative data in health information systems. Med Care 42:1066–1072PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2006

Authors and Affiliations

  • D. Weycker
    • 1
  • D. Macarios
    • 2
  • J. Edelsberg
    • 1
  • G. Oster
    • 1
  1. 1.Policy Analysis Inc. (PAI), Four Davis CourtBrooklineUSA
  2. 2.Amgen, Inc., Global Health Economics and Outcomes ResearchThousand OaksUSA

Personalised recommendations